Hjem › Atopisk dermatitis (eczem) › Georgia
Atopisk dermatitis (eczem) kliniske forsøg i Georgia
9 studier for Atopisk dermatitis (eczem) søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Skin Care Physicians of Georgia - Macon- Site Number : 8400034, Macon
RekruttererObservationsstudie
Alder 12 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Atlanta
- Novartis Investigative Site, Macon
RekruttererFase 2
Alder 18 til 100 · Alle køn · Opdateret 28. sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Atlanta
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Douglasville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07003425A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- Hamilton Research, LLC, Alpharetta
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07223697A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Georgia Skin & Cancer Center, Savannah
RekruttererFase 2
Alder 18 til 65 · Alle køn · Opdateret 28. aug. 2026 · NCT07599813A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Emory University School Of Medicine - Atlanta /ID# 268832, Atlanta
- Aeroallergy Research Laboratory /ID# 267247, Savannah
RekruttererFase 3
Alder 2 til 11 · Alle køn · Opdateret 6. aug. 2026 · NCT06461897A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Macon
RekruttererFase 3
6 Months – 11 Years · Alle køn · Opdateret 7. jul. 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Centricity Research Columbus Dermatology /ID# 266529, Columbus
- Cleaver Medical Group Dermatology /ID# 263788, Dawsonville
RekruttererFase 3
Alder 18 til 63 · Alle køn · Opdateret 6. jul. 2026 · NCT06389136Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.